Gyre Therapeutics Q1 2024 Earnings Report

Gyre Therapeutics EPS Results

• Actual EPS: $0.04
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Gyre Therapeutics Revenue Results

• Actual Revenue: $27.17 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Gyre Therapeutics Announcement Details

• Quarter: Q1 2024
• Date: 5/9/2024
• Time: N/A
• Conference Call Date: Thursday, May 9, 2024
• Conference Call Time: 7:00AM ET

Gyre Therapeutics (NASDAQ:GYRE) is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas. By leveraging its platform to validate novel targets and generate lead candidates, the company aims to address unmet medical needs where dysregulated lipid environments drive disease progression.

Headquartered in South San Francisco, California, Gyre Therapeutics was founded in 2021 and completed its initial public offering on the Nasdaq Global Market under the ticker symbol GYRE in mid-2023. Operating primarily in the United States, the company collaborates with academic researchers and industry partners to advance its discovery efforts. Through its innovative focus on membrane biochemistry, Gyre seeks to build a diversified portfolio of first-in-class small-molecule therapies.